Dec 9, 2025 12:48PM Sidoti Events, LLC's Year-End Virtual Investor Conference

Dec 9, 2025 12:48PM Sidoti Events, LLC's Year-End Virtual Investor Conference

Dec 9, 2025 12:48PM Sidoti Events, LLC's Year-End Virtual Investor Conference

Dec 9, 2025 12:48PM Sidoti Events, LLC's Year-End Virtual Investor Conference

Dec 8, 2025 02:54AM Evaxion presents cancer vaccine data at ASH meeting

Nov 21, 2025 08:48AM Evaxion Biotech registers 769,000 ADSs for selling shareholder

Nov 20, 2025 08:03AM Evaxion reports positive preclinical data for CMV vaccine antigens

Nov 6, 2025 08:08AM Evaxion Biotech (EVAX) Tops Q3 EPS by 1c

Nov 3, 2025 09:00AM Evaxion adds cancer vaccine candidate EVX-04 to development pipeline

Oct 30, 2025 08:03AM Evaxion raises $7.2 million, extends cash runway to second half of 2027

Oct 29, 2025 04:23PM Jones Trading Starts Evaxion Biotech (EVAX) at Buy

Oct 20, 2025 06:57AM H.C. Wainwright Reiterates Buy Rating on Evaxion Biotech (EVAX)

Oct 8, 2025 08:12AM Evaxion launches automated vaccine design module for AI platform

Sep 26, 2025 06:46AM Evaxion Biotech (EVAX) PT Raised to $16 at H.C. Wainwright

Sep 25, 2025 07:01AM Evaxion out-licenses EVX-B3 vaccine to MSD for $7.5 million upfront

Jul 11, 2025 08:01AM Evaxion converts €3.5 million EIB debt to equity via warrant purchase

Jun 25, 2025 08:01AM Evaxion Biotech (EVAX) expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Jun 3, 2025 09:16AM Evaxion Biotech (EVAX) receives grant funding to design new polio vaccine

May 28, 2025 06:56AM H.C. Wainwright Reiterates Buy Rating on Evaxion Biotech (EVAX)

May 27, 2025 04:20PM Evaxion Biotech (EVAX) Misses Q1 EPS by 1c

May 27, 2025 07:31AM Evaxion Biotech (EVAX) announces business update

Apr 28, 2025 08:01AM Evaxion Biotech (EVAX) presents EVX-01 data

Feb 14, 2025 08:03AM Evaxion Biotech (EVAX):Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination

Feb 3, 2025 06:50AM H.C. Wainwright Reiterates Buy Rating on Evaxion Biotech (EVAX)

Jan 30, 2025 08:01AM Evaxion Biotech (EVAX) announces pricing of $10.8 million public offering

Jan 28, 2025 08:15AM Evaxion Biotech (EVAX) granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Dec 30, 2024 08:02AM Evaxion Biotech (EVAX) to implement ADS ratio change

Dec 17, 2024 08:07AM Evaxion Biotech (EVAX) pursues agreement with EIB to bolster equity through conversion of debt into equity

Dec 12, 2024 08:04AM Evaxion Biotech (EVAX) establishes new AI-derived precision cancer vaccine concept

Nov 13, 2024 08:01AM Evaxion Biotech (EVAX) receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing

Nov 12, 2024 08:00AM Evaxion Biotech (EVAX) announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

Oct 31, 2024 04:28PM Evaxion Biotech (EVAX) Misses Q3 EPS by 4c

Oct 9, 2024 08:02AM Evaxion Biotech (EVAX) Reports strong validation of AI-Immunology platform in multiple clinical trials

Oct 3, 2024 08:01AM Evaxion Biotech (EVAX): Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology platform

Sep 27, 2024 06:52AM H.C. Wainwright Reiterates Buy Rating on Evaxion Biotech (EVAX)

Sep 26, 2024 07:31AM Evaxion Biotech (EVAX) expands vaccine development collaboration with MSD

Sep 20, 2024 06:55AM H.C. Wainwright Reiterates Buy Rating on Evaxion Biotech (EVAX)

Sep 19, 2024 08:01AM Evaxion Biotech (EVAX) launches improved AI-Immunology platform for vaccine antigen prediction

Sep 16, 2024 07:00AM Evaxion Biotech (EVAX) reports convincing one-year data from phase 2 trial of EVX-01

Sep 9, 2024 08:03AM Evaxion Biotech (EVAX) Reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01

Sep 9, 2024 07:07AM Evaxion Biotech (EVAX) obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2

Jul 3, 2024 08:05AM Evaxion Biotech (EVAX) Provides Shareholder Update

Jun 26, 2024 07:31AM Evaxion Biotech (EVAX) Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method

Jun 17, 2024 08:45AM Evaxion Biotech (EVAX) Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal